

AMENDMENTSIN THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Claims 1, 8, 9, 12-17, and 39-48 are pending in this Application.


Claims 2-7, 10-11, and 18-38 were previously canceled.

Claims 24-30 are withdrawn from consideration but are subject to rejoinder.

Claims 1, 9, 12, 13, and 40-43 are currently amended.

Claims 8, 14-17, 39, and 44-48 were previously presented.

1. (currently amended) A compound represented by formula I,



or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof, and wherein,

each W is CR¹;

each R¹ is independently selected from -H and -A-R⁷; provided one of R¹ is -A-R⁷ and is located at the 5-position of the indolinone ring, wherein, only for said -A-R⁷, R⁷ must be a piperidin-4-yl, and where the nitrogen of the piperidin-4-yl of -A-R⁷ is optionally substituted with one group selected from alkyl, aryl, arylalkyl, ~~heterocyclalkyl, a~~ monocyclic heteroalicyclicalkyl, heterocycl, acyl, and sulfonyl[[,]];

A is NH;

L is NR³;

Q is C;

R^2 and R^3 are each -H;

R^4 and R^5 are each independently selected from -H, $-OR^6$, $-NR^6R^7$, $-S(O)_{0-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, -CN, $-NO_2$, $-NH_2$, halogen, trihalomethyl, alkyl, 1,3-dioxo-isoindol-2-ylethyl, and aryl- R^7 ; or


R^4 and R^5 , when taken together, form a six-membered aromatic ring system containing zero nitrogens, said six-membered aromatic ring system is optionally substituted with between zero and four of R^{15} ;

R^6 is selected from -H, and C_{1-8} alkyl, aryl C_{1-8} alkyl, heterocyclyl C_{1-8} alkyl, aryl, and heterocyclyl;

R^7 , for other than R^7 in $-A-R^7$, is selected from -H, and C_{1-8} alkyl, aryl C_{1-8} alkyl, heterocyclyl C_{1-8} alkyl, aryl, heterocyclyl; ~~provided that there are at least two carbons between any heteroatom of R^7 and either nitrogen to which R^2 and R^3 are attached;[[or]]~~

R^8 is -H, $-NO_2$, -CN, $-OR^6$, or [[and]] C_{1-8} alkyl;

X is selected from one of the following [[six]] formulae:



wherein m is zero to five, n is zero to three, and Z is CR^{10} ;


R^{10} is selected from -H, halogen, trihalomethyl, $-NH_2$, $-NO_2$, $-OR^6$, $-N=CNR^6R^7$, $-NR^6R^7$, $-N(R^6)C(=NR^8)NR^6R^7$, $-SR^6$, $-S(O)_{1-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)N(OR^6)R^7$, $-C(=NR^8)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, and R^7 ;

K is O; and

each R^{15} is independently selected from -H, halogen, $-OR^6$, and C_{1-8} alkyl- NH_2 , ~~$-NO_2$, $-OR^6$, $-N=CNR^6R^7$, $-NR^6R^7$, $-N(R^6)C(=NR^8)NR^6R^7$, $-SR^6$, $-S(O)_{1-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)N(OR^6)R^7$, $-C(=NR^8)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, and R^7 .~~


Claims 2-7 (previously canceled)

8. (previously presented) The compound according to claim 1, wherein X is



m is 0 to 3, and R¹⁰ is selected from -H, halogen, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, -C(O)R⁷, and -C₁₋₈alkyl; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

9. (currently amended) A compound of formula II:



or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof;

wherein:

A is NH;

R⁷, in -A-R⁷, is piperidin-4-yl and is located on the 5-position of the indolinone ring; wherein the ring nitrogen of R⁷ is substituted with a group R¹²; and

R¹² is selected from a) -H, b) C₁₋₈alkyl, c) -SO₂R⁶, d) -SO₂NR⁶R⁷, e) -CO₂R⁶, f) -C(O)NR⁶R⁷, and g) -C(O)R⁷; and where the C₁₋₈alkyl in b) is optionally substituted with one to five groups independently selected from alkyl, aryl, arylalkyl, ~~heterocyclylalkyl~~, ~~heterocyclyl~~, ~~a monocyclic heteroalicyclic~~, alkoxy, ~~substituted alkoxy~~, amino, alkylamino, ~~and~~ dialkylamino, ~~amidino~~, aryloxy, arylalkyloxy, ~~carboxy~~, ~~acyloxy~~, ~~benzyloxy~~, ~~carbonylamino~~, ~~cyano~~, ~~acyl~~, ~~halogen~~, ~~hydroxy~~, ~~nitro~~, ~~sulfanyl~~, ~~sulfinyl~~, ~~sulfonyl~~, ~~halogen~~, ~~hydroxy~~, ~~oxo~~, ~~carbamyl~~, and ~~acylamino~~;

R^6 is selected from -H and C_{1-8} alkyl;

R^4 and R^5 are each independently selected from -H, $-OR^6$, $-NR^6R^7$, $-S(O)_{0-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, -CN, $-NO_2$, $-NH_2$, halogen, trihalomethyl, alkyl, 1,3-dioxo-isoindol-2-ylethyl, and aryl- R^7 ; or

R^4 and R^5 , when taken together, form a six-membered aromatic ring system containing zero nitrogens, said six-membered aromatic ring system is optionally substituted with between zero and four of R^{15} ;

R^{10} is selected from -H, halogen, $-NH_2$, $-NO_2$, $-OR^6$, $-N=CNR^6R^7$, $-NR^6R^7$, $-N(R^6)C(=NR^8)NR^6R^7$, $-SR^6$, $-S(O)_{1-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)N(OR^6)R^7$, $-C(=NR^8)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, and C_{1-8} alkyl;

m is 0 to 3;


R^7 , for other than R^7 in $A-R^7$, is selected from -H, and C_{1-8} alkyl, ~~aryl~~ C_{1-8} alkyl, ~~heterocyclyl~~ C_{1-8} alkyl, and ~~heterocyclyl~~;

R^8 is -H, $-NO_2$, -CN, $-OR^6$, or $[[\text{and}]]C_{1-8}$ alkyl; and

each R^{15} is independently selected from -H, halogen, ~~$-OR^6$, and C_{1-8} alkyl~~ $-NH_2$, $-NO_2$, ~~$-OR^6$, $-N=CNR^6R^7$, $-NR^6R^7$, $-N(R^6)C(=NR^8)NR^6R^7$, $-SR^6$, $-S(O)_{1-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)N(OR^6)R^7$, $-C(=NR^8)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, and R^7~~ .

Claims 10-11 (previously canceled)

12. (currently amended) A compound according to formula III.



III

or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof;

where

R^{12} is a C_{1-4} alkylene;

R^{13} is selected from -H, an alkoxy group, amino, alkylamino, dialkylamino, and ~~an~~ a monocyclic heteroalicyclic, with the proviso that a heteroatom of said alkoxy group, amino group, alkylamino group, dialkylamino group, and heteroalicyclic cannot be attached to a carbon of R^{12} which is directly attached to the ring nitrogen of the piperidine in formula III;

R^4 and R^5 are each independently selected from -H, $-OR^6$, $-NR^6R^7$, $-S(O)_{0-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, -CN, $-NO_2$, $-NH_2$, halogen, trihalomethyl, alkyl, 1,3-dioxo-isindol-2-ylethyl, and aryl- R^7 ; or

R^4 and R^5 , when taken together, form a six-membered aromatic ring system containing zero nitrogens, said six-membered aromatic ring system is optionally substituted with between zero and four of R^{15} ;

R^6 is selected from -H and C_{1-8} alkyl;

R^7 is selected from -H, and C_{1-8} alkyl, ~~aryl~~ C_{1-8} alkyl, ~~heterocyclyl~~ C_{1-8} alkyl, ~~aryl~~, and ~~heterocyclyl~~;


R^8 is -H, $-NO_2$, -CN, $-OR^6$, or ~~[[and]]~~ C_{1-8} alkyl;

R^{10} is selected from -H, halogen, $-NH_2$, $-NO_2$, $-OR^6$, $-N=CNR^6R^7$, $-NR^6R^7$, $-N(R^6)C(=NR^8)NR^6R^7$, $-SR^6$, $-S(O)_{1-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)N(OR^6)R^7$, $-C(=NR^8)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, and C_{1-8} alkyl;

m is 0 to 3; and

each R^{15} is independently selected from -H, halogen, $-OR^6$, and C_{1-8} alkyl- NH_2 , ~~$-NO_2$, $-OR^6$, $-N=CNR^6R^7$, $-NR^6R^7$, $-N(R^6)C(=NR^8)NR^6R^7$, $-SR^6$, $-S(O)_{1-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)N(OR^6)R^7$, $-C(=NR^8)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, and R^7~~ .

13. (currently amended) A compound according to formula IIIa,



IIIa

or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof;

wherein R^{12} is a C_{2-4} alkylene;

R^{13} is selected from -H, an alkoxy group, an amino group, an alkylamino group, a dialkylamino group and ~~an~~ a monocyclic heteroalicyclic;

R^{10} is selected from -H, halogen, perfluoroalkyl, $-NH_2$, $-NO_2$, $-OR^6$, $-N=CNR^6R^7$, $-NR^6R^7$, $-N(R^6)C(=NR^8)NR^6R^7$, $-SR^6$, $-S(O)_{1-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)N(OR^6)R^7$, $-C(=NR^8)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$;

R^4 and R^5 are each independently selected from -H, halogen, and C_{1-4} alkyl; or R^4 and R^5 combined are a phenyl where the phenyl is optionally substituted with one to five groups independently selected from alkyl, aryl, ~~arylalkyl, heterocyclylalkyl, heterocyclyl,~~ alkoxy, ~~substituted alkoxy, methylenedioxy, amino, alkylamino, dialkylamino, amidino,~~ aryloxy, ~~arylalkyloxy, carboxy, acyloxy, benzyloxycarbonylamino, cyano, acyl, and~~ halogen, ~~hydroxy, nitro, sulfanyl, sulfinyl, sulfonyl, halogen, hydroxy, carbamyl, and~~ acylamino;

m is 0-3;

R^6 is selected from -H and C_{1-8} alkyl, ~~said C_{1-8} alkyl substituted with at least one of $-CO_2H$ and $-CO_2C_{1-8}$ alkyl;~~

R^7 is selected from -H, and C_{1-8} alkyl, ~~aryl C_{1-8} alkyl, heterocyclyl C_{1-8} alkyl, aryl, and~~ ~~heterocyclyl;~~ and

R^8 is -H, $-NO_2$, $-CN$, $-OR^6$, or $[[\text{and}]]C_{1-8}$ alkyl.

14. **(previously presented)** The compound according to claim 13, wherein R^{12} is an ethylene; R^{10} is halogen; R^4 and R^5 are each independently selected from -H, halogen, and C_{1-2} alkyl; and m is 1-3; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

15. **(previously presented)** The compound according to claim 14, wherein each R^{10} is independently selected from fluorine and chlorine; R^4 and R^5 are each independently selected from -H and C_{1-2} alkyl; and m is 1-3; or a single stereoisomer, a single geometric

isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

16. **(previously presented)** The compound according to claim 15, wherein each R¹⁰ is independently selected from fluorine and chlorine; R⁴ and R⁵ are each independently selected from -H and -CH₃; and m is 1-2; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

17. **(previously presented)** The compound according to claim 16, wherein R¹⁰ is fluorine; R⁴ and R⁵ are each independently selected from -H and -CH₃; and m is 1; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

Claims 18-38 **(previously canceled)**

39. **(previously presented)** The compound according to claim 17, selected from:

49	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
51	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
58	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
70	(3Z)-3-[(3-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one;
78	(3Z)-3-[(4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one
82	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-{{1-(2-piperidin-1-ylethyl)piperidin-4-yl} amino}-1,3-dihydro-2H-indol-2-one;
83	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-{{1-(2-morpholin-4-ylethyl)piperidin-4-yl} amino}-1,3-dihydro-2H-indol-2-one;
84	(3Z)-5-({1-[2-(diethylamino)ethyl]piperidin-4-yl} amino)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
85	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-{{1-(2-pyrrolidin-1-ylethyl)piperidin-4-yl} amino}-1,3-dihydro-2H-indol-2-one;
106	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
107	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(2-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one; and

113	(3Z)-3-[(2-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
-----	--

and where the compound is optionally as a pharmaceutically acceptable salt thereof.

40. (currently amended) The Compound of Claim 9 selected from

22	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-(piperidin-4-ylamino)-1,3-dihydro-2H-indol-2-one;
28	<u>2-(2-{2-[(Z)-{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3H-indol-3-ylidene}(phenyl)methyl]-1H-imidazol-4-yl}ethyl)-1H-isoindole-1,3(2H)-dione;</u>
30	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[[1-(methylsulfonyl)piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one;
81	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-(piperidin-4-ylamino)-1,3-dihydro-2H-indol-2-one; and
93	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[[1-(methylsulfonyl)piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one;

and where the compound is optionally as a pharmaceutically acceptable salt thereof.

41. (currently amended) The compound of Claim 12 selected from

4	(3Z)-3-[[5-(methyloxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-5-[[1-(phenylmethyl)pyrrolidin-3-yl]amino]-1,3-dihydro-2H-indol-2-one;
6	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methyloxy)-1H-benzimidazol-2-yl](4-methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one;
12	(3Z)-3-[1H-benzimidazol-2-yl(4-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
13	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one;
14	(3Z)-5-[(1-ethylpiperidin-4-yl)oxy]-3-[[5-(methyloxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-one;
28	<u>2-(2-{2-[(Z)-{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3H-indol-3-ylidene}(phenyl)methyl]-1H-imidazol-4-yl}ethyl)-1H-isoindole-1,3(2H)-dione;</u>
50	(3Z)-3-[1H-benzimidazol-2-yl(3-fluoro-4-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
52	(3Z)-3-[1H-benzimidazol-2-yl(4-fluoro-3-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
57	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluoro-4-methylphenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
59	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(4-propylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one;
63	(3Z)-3-[(3-fluoro-4-methylphenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
64	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-methyl-1H-imidazol-2-yl)(4-methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one;
67	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluoro-4-methylphenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;

69	(3Z)-3-[1 <i>H</i> -imidazol-2-yl(4-methylphenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;
77	(3Z)-3-[(4-methyl-1 <i>H</i> -imidazol-2-yl)(4-methylphenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;
86	(3Z)-3-[1 <i>H</i> -imidazol-2-yl(4-methylphenyl)methylidene]-5-[(1-methylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
88	ethyl 2-[(<i>Z</i>)-(3-fluorophenyl)[5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-2-oxo-1,2-dihydro-3 <i>H</i> -indol-3-ylidene]methyl]-4-methyl-1 <i>H</i> -imidazole-5-carboxylate;
94	(3Z)-3-[1 <i>H</i> -imidazol-2-yl(4-propylphenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;
95	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-phenyl-1 <i>H</i> -imidazol-2-yl)methylidene]-1,3-dihydro-2 <i>H</i> -indol-2-one;
96	(3Z)-3-[(3-fluorophenyl)(4-phenyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one; and
97	(3Z)-3-[(3-fluoro-4-methylphenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;

and where the compound is optionally as a pharmaceutically acceptable salt thereof.

42. (currently amended) The compound of Claim 13 selected from

3	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methyloxy)-1 <i>H</i> -benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2 <i>H</i> -indol-2-one;
4	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1 <i>H</i> -imidazol-2-yl(phenyl)methylidene]-1,3-dihydro-2 <i>H</i> -indol-2-one;
5	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methyloxy)-1 <i>H</i> -benzimidazol-2-yl][4-(methyloxy)phenyl]methylidene]-1,3-dihydro-2 <i>H</i> -indol-2-one;
7	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(4-nitrophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
8	(3Z)-3-{1 <i>H</i> -benzimidazol-2-yl[4-(methyloxy)phenyl]methylidene}-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
9	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(phenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
11	(3Z)-3-[(4-aminophenyl)(1 <i>H</i> -benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
15	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{1 <i>H</i> -imidazol-2-yl[4-(methyloxy)phenyl]methylidene}-1,3-dihydro-2 <i>H</i> -indol-2-one;
16	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
17	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
18	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
19	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(3-nitrophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;

21	(3Z)-3-[(3-aminophenyl)(1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
23	3-((Z)-1H-benzimidazol-2-yl{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)benzenecarboximidamide;
24	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one;
26	(3Z)-3-{1H-benzimidazol-2-yl[3-(methyloxy)phenyl]methylidene}-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
27	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
29	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-({1-[2-(dimethylamino)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one;
38	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one;
39	(3Z)-3-{1H-benzimidazol-2-yl[3-(methyloxy)phenyl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one;
42	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one
45	(3Z)-3-[1H-benzimidazol-2-yl(4-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
46	(3Z)-3-[1H-benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one;
47	(3Z)-3-[1H-benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one;
55	(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(phenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
56	(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
60	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{1H-imidazol-2-yl[4-(trifluoromethyl)phenyl]methylidene}-1,3-dihydro-2H-indol-2-one;
61	(3E)-3-[(3,5-difluorophenyl)(5-fluoro-1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
62	(3Z)-3-[(3,5-difluorophenyl)(5-fluoro-1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
65	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[3-fluoro-4-(trifluoromethyl)phenyl](1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
71	(3Z)-3-{1H-imidazol-2-yl[4-(trifluoromethyl)phenyl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one;
72	(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one;
89	(3Z)-3-[1H-imidazol-2-yl(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one;
90	(3Z)-3-{1H-imidazol-2-yl[4-(methyloxy)phenyl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one;
92	(3Z)-3-[[3-fluoro-4-(trifluoromethyl)phenyl](1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one;

100	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[2-fluoro-4-(trifluoromethyl)phenyl](1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
101	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{(4-methyl-1H-imidazol-2-yl)[4-(trifluoromethyl)phenyl]methylidene}-1,3-dihydro-2H-indol-2-one;
103	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[3-fluoro-4-(trifluoromethyl)phenyl](4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
108	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[2-fluoro-4-(trifluoromethyl)phenyl](4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
114	(3Z)-3-[(3-trifluoromethylphenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
115	(3Z)-3-[(3-trifluoromethylphenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
116	(3Z)-3-[(2,4-dichloro-5-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one; and
117	(3Z)-3-[(2,4-dichloro-5-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;

where the compound is optionally as a pharmaceutically acceptable salt thereof.

43. (currently amended) The compound of Claim 16 selected from

40	(3Z)-3-[(3-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one
41	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one
42	(3Z)-3-[(1H-benzimidazol-2-yl)(3,5-difluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one
48	(3Z)-3-[(3-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
53	(3Z)-3-[(3-chloro-4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
54	(3Z)-3-[(3,4-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
66	(3Z)-3-[(4-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
73	(3Z)-3-[(3,5-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
74	(3Z)-3-[(3,5-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
75	(3Z)-3-[(3,5-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one
76	(3Z)-3-[(3,5-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one
79	(3Z)-3-[(3,4-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one
80	(3Z)-3-[(3-chloro-4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one

91	(3Z)-3-[(4-chlorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one
102	(3Z)-3-[(4-chlorophenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
104	(3Z)-3-[(3,4-difluorophenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
105	(3Z)-3-[(3-chloro-4-fluorophenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
109	(3Z)-3-[(2,3-difluorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
110	(3Z)-3-[(2,3-difluorophenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
111	(3Z)-3-[(2,4-difluorophenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
112	(3Z)-3-[(2,4-difluorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
118	(3Z)-3-[(4-chloro-2-fluorophenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one

where the compound is optionally as a pharmaceutically acceptable salt thereof.

44. **(previously presented)** The compound of Claim 39 named (3Z)-3-[(2-fluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one; where the compound is optionally as a pharmaceutically acceptable salt thereof.

45. **(previously presented)** The compound of Claim 39 named (3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one; where the compound is optionally as a pharmaceutically acceptable salt thereof.

46. **(previously presented)** The Compound of Claim 1 selected from (3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{1*H*-imidazol-2-yl[6-(trifluoromethyl)pyridin-3-yl]methylidene}-1,3-dihydro-2*H*-indol-2-one and (3Z)-3-{1*H*-imidazol-2-yl[6-(trifluoromethyl)pyridin-3-yl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one; or a single geometric isomer thereof, optionally as a pharmaceutically acceptable salt thereof.

47. **(previously presented)** A pharmaceutical composition comprising a compound according to Claim 1, 9, 12, 13, 39, 40, 41, 42, 43, or 46 or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, where

the compound is optionally as a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

48. **(previously presented)** A pharmaceutical composition comprising a compound according to Claim 44 or 45, where the compound is optionally as a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.